Biodesix Q3 lung diagnostic revenue up 51% YoY; launches 72-hour NGS test

BIODESIX INC

2022-Q3 EPS reported -$1.09 revenue$47,282,000

Total revenue $6.5M; lung diagnostic revenue $4.5M (+51% YoY), services $1.5M (+133%), COVID-19 testing $0.5M (-91%).
Gross margin 58% (up from 40% in Q2 2021); operating expenses $16.9M (+46%).
Net loss $11.5M (+30%); includes $3.1M non-cash PPP loan forgiveness gain.
Cash and cash equivalents $47.9M as of Sept 30, 2021.
Launched 72-hour liquid NGS test ahead of schedule; broad US launch targeted for Q1 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.